Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $329.00 million. The enterprise value is $132.36 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 108.22 million shares outstanding. The number of shares has increased by 14.70% in one year.
| Current Share Class | 108.22M |
| Shares Outstanding | 108.22M |
| Shares Change (YoY) | +14.70% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 67.38% |
| Float | 78.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.30, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.30 |
| Quick Ratio | 7.15 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -130.71 |
Financial Efficiency
Return on equity (ROE) is -74.88% and return on invested capital (ROIC) is -44.51%.
| Return on Equity (ROE) | -74.88% |
| Return on Assets (ROA) | -40.56% |
| Return on Invested Capital (ROIC) | -44.51% |
| Return on Capital Employed (ROCE) | -73.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$805,726 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.25% in the last 52 weeks. The beta is 0.65, so RCKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -78.25% |
| 50-Day Moving Average | 3.43 |
| 200-Day Moving Average | 5.04 |
| Relative Strength Index (RSI) | 37.19 |
| Average Volume (20 Days) | 1,889,119 |
Short Selling Information
The latest short interest is 11.03 million, so 10.20% of the outstanding shares have been sold short.
| Short Interest | 11.03M |
| Short Previous Month | 12.40M |
| Short % of Shares Out | 10.20% |
| Short % of Float | 13.97% |
| Short Ratio (days to cover) | 3.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -247.18M |
| Pretax Income | -240.91M |
| Net Income | -240.91M |
| EBITDA | -236.01M |
| EBIT | -247.18M |
| Earnings Per Share (EPS) | -$2.24 |
Full Income Statement Balance Sheet
The company has $222.76 million in cash and $25.05 million in debt, giving a net cash position of $197.71 million or $1.83 per share.
| Cash & Cash Equivalents | 222.76M |
| Total Debt | 25.05M |
| Net Cash | 197.71M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 313.67M |
| Book Value Per Share | 2.90 |
| Working Capital | 196.51M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$202.12 million and capital expenditures -$669,000, giving a free cash flow of -$202.79 million.
| Operating Cash Flow | -202.12M |
| Capital Expenditures | -669,000 |
| Free Cash Flow | -202.79M |
| FCF Per Share | -$1.87 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.70% |
| Shareholder Yield | -14.70% |
| Earnings Yield | -72.99% |
| FCF Yield | -61.44% |
Dividend Details Analyst Forecast
The average price target for RCKT is $12.88, which is 323.68% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.88 |
| Price Target Difference | 323.68% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -24.42% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |